Table 2.
Baseline characteristics of the patients with Rheumatoid arthritis (RA), Osteoarthritis (OA) and heathy controls (HCs).
| Features | RA (n = 65) | OA (n = 35) | HCs (n = 40) | P |
| Mean age (yr) | 54.72 ± 11.43 | 55.05 ± 10.73 | 50.33 ± 9.13 | .87∗ |
| Gender (Male/ Female) | 27/38 | 17/18 | 18/22 | .64∗ |
| Disease duration (yr) | 10.91 ± 4.91 | 9.96 ± 3.95 | – | .59† |
| CRP, mg/dl | 17.5 ± 11.1 | 12.5 ± 10.7 | 7.7 ± 4.6 | <.001∗ |
| ESR, (mm/h) | 26.0 ± 15.2 | 18.1 ± 14.0 | 7.0 ± 5.7 | <.001∗ |
| Calprotectin, μg/mL | 10.01 (5.01–14.44) | 7.72 (4.69–12.68) | 4.44 (2.62–7.34) | <.001∗ |
| RF, no. positive (%) | 37/65 (56.92%) | – | – | |
| Anti-CCP positivity, n (%) | 35/65 (53.85%) | – | – | |
| TJC [n]; median (range) | 7.0 (0.0–28.0) | – | – | |
| SJC [n]; median (range) | 4.0 (0.0–27.0) | – | – | |
| DAS28-ESR score | 3.74 (2.52-6.07) | – | – | |
| CDAI score | 15.78 (2.94-34.37) | – | – | |
| SDAI | 13.85 (4.64–39.65) | – | – | |
| csDMARDs, n (%) | 54/65 (83.08%) | – | ||
| bDMARDs, n (%) | 11/65 (16.92%) | – |
Values are shown as mean ± standard deviation (SD) or median (interquartile range).
Comparison among three groups, determined by One-way analysis of variance (ANOVA), Kruskal–Wallis test by ranks, or χ2 test.
Comparison between RA and OA groups, determined by Mann–Whitney-U-test.
RA = Rheumatoid arthritis; OA = Osteoarthritis; HCs = heathy controls; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RF = rheumatoid factor; Anti-CCP = anti-cyclic citrullinated peptides; TJC = Tender joint count; SJC swollen joint count; DAS28-ESR = Disease Activity Score for 28 joints with erythrocyte sedimentation rate; CDAI = Clinical Disease Activity Index; SDAI = Simplified Disease Activity Index; csDMARDs = conventional synthetic disease-modifying antirheumatic drugs; bDMARDs = biologic disease-modifying antirheumatic drugs.